Neuroanesthesia & neurocritical care
Valproic acid as adjuvant treatment for convulsive status epilepticus: a randomised clinical trial
Primary resultResult — go to the resultAdjusted relative risk 1.04 95% CI 0.89–1.19Authors' conclusion
VPA added to the recommended strategy for adult GCSE is well tolerated but did not increase the proportion of patients hospital-discharged by day 15.
Study context
- Population
- Adults admitted to ICUs for de novo established generalised convulsive status epilepticus (GCSE), 16 French hospitals, 2013–2018; standard care of benzodiazepine and a second-line anti-seizure medicine (ASM) (except valproic acid (VPA))
- Participants
- 244 adults · 16 French hospitals
- Comparison
- VPA vs placebo, added to standard stepwise care
- VPAn = 126
- Placebon = 118reference
- Primary endpoint
- Proportion of patients discharged from hospital by day 15
- Follow-up
- Day 15
Methodological detailsmulticentre, double-blind
- Multicentre
- Double-blind
Primary result
As reported in the abstract
Adjusted relative risk
1.04
95% CI 0.89–1.19
P = 0.58
Events by treatment group
VPA vs Placebo
adjusted RR 1.04 (95% CI 0.89–1.19); P = 0.58
Secondary outcomes
Seizure control, adverse events, cognition at day 90
- No between-group differences for secondary outcomes
Original publication
Valproic acid as adjuvant treatment for convulsive status epilepticus: a randomised clinical trial. Crit Care. Published 9 January 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →